
Overview

Useful For

Supporting the diagnosis of Lyme disease in conjunction with serologic testing

Specific indications including testing skin biopsies when a rash lesion is not characteristic of erythema migrans and testing synovial fluid or synovium to support the diagnosis of Lyme arthritis

This test **should not be used** to screen asymptomatic patients.

Testing Algorithm

The following algorithms are available:

- [Acute Tick-Borne Disease Testing Algorithm](#)
- [Meningitis/Encephalitis Panel Algorithm](#)

Special Instructions

- [Acute Tickborne Disease Testing Algorithm](#)
- [Meningitis/Encephalitis Panel Algorithm](#)

Method Name

Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization

NY State Available

No

Specimen

Specimen Type

Varies

Ordering Guidance

This assay does not detect *Borrelia miyamotoi*. If infection with this organism is suspected, order BMIYB / *Borrelia miyamotoi* Detection, PCR, Blood or BMIYC / *Borrelia miyamotoi* Detection, PCR, Spinal Fluid.

Necessary Information

Specimen source is required.

Specimen Required

Submit only 1 of the following specimens:

Specimen Type: Spinal fluid

Container/Tube: Sterile vial

Specimen Volume: 1 mL

Collection Instructions: Label specimen as spinal fluid.

Specimen Type: Synovial fluid

Container/Tube: Sterile vial

Specimen Volume: 1 mL

Collection Instructions: Label specimen as synovial fluid.

Specimen Type: Tissue (fresh only)

Sources: Skin or synovial biopsy

Container/Tube: Sterile container with normal saline

Specimen Volume: Approximately 4 mm(3)

Collection Instructions:

1. Submit only fresh tissue.
2. Skin biopsies:
 - a. Wash biopsy site with an antiseptic soap. Thoroughly rinse area with sterile water. Do not use alcohol or iodine preparations. A local anesthetic may be used.
 - b. Biopsy specimens are best taken by punch biopsy to include full thickness of dermis.
3. Label specimen with source of tissue.

Specimen Minimum Volume

Spinal fluid, synovial fluid: 0.3 mL; Tissue: See Specimen Required

Reject Due To

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Varies	Refrigerated (preferred)	7 days	
	Frozen	7 days	

Clinical & Interpretive

Clinical Information

Lyme disease is a multisystem and multistage tick-transmitted infection caused by spirochetal bacteria in the *Borrelia burgdorferi* sensu lato (Bbsl) complex.(1) Nearly all human infections are caused by 3 Bbsl species; *B burgdorferi* sensu stricto (hereafter referred to as *B burgdorferi*) is the primary cause of Lyme disease in North America, while *Borrelia afzelii* and *Borrelia garinii* are the primary causes of Lyme disease in Europe. In 2012, *Borrelia mayonii* has been identified as a less common cause of Lyme disease in the upper Midwestern United States.(2,3) This organism has only

been detected in patients with exposure to ticks in Minnesota and Wisconsin and has not been detected in over 10,000 specimens from patients in other states including regions of northeast where Lyme disease is endemic.

Lyme disease is the most commonly reported tick-borne infection in Europe and North America, causing an estimated 300,000 cases in the United States each year and 85,000 cases in Europe.(4,5) The clinical features of Lyme disease are broad and may be confused with various immune and inflammatory disorders. The classic presenting sign of early localized Lyme disease caused by *B burgdorferi* is erythema migrans (EM), which occurs in approximately 80% of individuals. Other early signs and symptoms include malaise, headache, fever, lymphadenopathy, and myalgia. Arthritis, neurological disease, and cardiac disease may be later stage manifestations. EM has also been seen in patients with *B mayonii* infection, but diffuse rashes are more commonly reported.(2) The chronic skin condition, acrodermatitis chronica atrophicans, is also associated with *B afzelii* infection.

The presence of EM in the appropriate clinical setting is considered diagnostic for Lyme disease; no confirmatory laboratory testing is needed. In the absence of a characteristic EM lesion, serologic testing is the diagnostic method of choice for Lyme disease.(6) However, serology may not be positive until 1 to 2 weeks after onset of symptoms and may show decreased sensitivity for detection of infection with *B mayonii*. Therefore, detection of Bbsl DNA using polymerase chain reaction (PCR) may be a useful adjunct to serologic testing for detection of acute disease. PCR has shown utility for detection of *Borrelia* DNA from skin biopsies of Lyme-associated rashes and can be used to detect *Borrelia* DNA from synovial fluid and synovium biopsies. Less commonly, *Borrelia* DNA can be detected in cerebrospinal fluid.(7) Lyme PCR should always be performed in conjunction with US Food and Drug Administration approved serologic tests, and the results should be correlated with serologic and epidemiologic data and clinical presentation of the patient.(8) The Mayo Clinic Lyme PCR test detects and differentiates the main causes of Lyme disease in North America (*B burgdorferi* and *B mayonii*) and Europe (*B afzelii* and *B garinii*). (2,7)

Reference Values

Negative

Reference values apply to all ages.

Interpretation

A positive result indicates the presence of DNA from *Borrelia burgdorferi*, *Borrelia mayonii*, *Borrelia afzelii*, or *Borrelia garinii*, the main agents of Lyme disease.

A negative result indicates the absence of detectable target DNA in the specimen. Due to the clinical sensitivity limitations of the polymerase chain reaction assay, a negative result does not preclude the presence of the organism or active Lyme disease.

Cautions

Serologic tests are recommended for diagnosis of Lyme disease. Polymerase chain reaction (PCR) may play an adjunctive role but may not detect *Borrelia burgdorferi* DNA from cerebrospinal fluid (CSF) in cases of active or chronic disease. The presence of inhibitory substances may also cause a false-negative result. If clinical features of illness are highly indicative of Lyme neuroborreliosis, serologic testing on CSF is warranted. PCR test results should be used as an aid in diagnosis and not considered diagnostic by themselves. These results should be correlated with serologic and epidemiologic data and clinical presentation of the patient.

Testing of CSF by PCR in patients with suspected Lyme neuroborreliosis should be requested only on patients with

positive *Borrelia burgdorferi* antibody in serum confirmed by Western blot assay (LYWB / Lyme Disease Antibody, Immunoblot, Serum) and with abnormal CSF findings (elevated protein and white blood cells >10 cells/high-power field).

Concurrent infections with multiple tick-borne pathogens, including *Ehrlichia muris eauclairensis*, *Anaplasma phagocytophilum*, *Babesia microti*, and *Borrelia miyamotoi* (a relapsing fever *Borrelia*) have been reported in United States, and consideration should be given to testing for other pathogens, if clinically indicated.

This assay detects most members of the *Borrelia burgdorferi* sensu lato (Bbsl) complex, including *Borrelia andersonii*, *Borrelia americana*, and *Borrelia bissettii*, which have been rarely detected in humans. Detection of DNA from these organisms would be reported as an atypical result and prompt additional laboratory testing to further identify the DNA present. The sensitivity of this assay for detecting these organisms has not been determined.

This assay also detects some members of the Bbsl complex that are not considered to be human pathogens but may be found in ticks and other animals. Therefore, this assay should not be used to test nonhuman specimens.

Supportive Data

The following validation data supports the use of this assay for clinical testing.

Accuracy:

Results from this real-time polymerase chain reaction (PCR) assay on the LightCycler were compared to those generated using conventional PCR assay for *Borrelia burgdorferi* and *Borrelia mayonii*. Specimens included previously tested patient samples and samples spiked with diluted thermally-induced bacteria (TIB) plasmid. A total of 50 whole blood specimens (26 positive and 24 negative) were tested.

Accuracy was 96%.

Limit of Detection:

The limit of detection (LOD) was established using dilutions of TIB plasmid.

LOD: Approximately 12.5 copies per microliter.

Analytical Specificity:

Samples were tested in the presence of common interfering substances, such as blood, bacteria, clots, and high viscosity, to ensure results remained positive and/or negative. No interferences noted.

Precision:

Inter-assay and intra-assay precision were 100%.

Reference Range:

The reference range for this assay is negative. This assay is only to be used for patients with a clinical history and symptoms consistent with Lyme and must be interpreted in the context of serologic tests, which are the gold standard for diagnosis of Lyme disease.

Reportable Range:

This is a qualitative assay, and the results are reported as negative or positive for targeted *Borrelia burgdorferi*.

Clinical Reference

1. Stanek G, Wormser GP, Gray J, Strle F. Lyme borreliosis. *Lancet*. 2012;379(9814):461-473
2. Pritt BS, Mead PS, Johnson, DK, et al. Identification of a novel pathogenic *Borrelia* species causing Lyme borreliosis with unusually high levels of spirochetemia: a descriptive study. *Lancet Infect Dis*. 2016;16(5):556-564
3. Pritt BS, Respicio-Kingry LB, Sloan LM, et al. *Borrelia mayonii* sp. nov., a member of the *Borrelia burgdorferi* sensu lato complex, detected in patients and ticks in the upper midwestern United States. *Int J Sys Evol Microbiol*. 2016;66(11):4878-4880
4. Hinckley AF, Connally NP, Meek JI, et al. Lyme disease testing by large commercial laboratories in the United States. *Clin Infect Dis*. 2014;59(5):676-681
5. Lindgren E, Jaenson TGT: Lyme borreliosis in Europe: influences of climate and climate change, epidemiology, ecology and adaptation measures. World Health Organization; 2006
6. Centers for Disease Control and Prevention. Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. *MMWR Morb Mortal Wkly Rep*. 1995;44(31):590-591
7. Babady NE, Sloan LM, Vetter EA, Patel R, Binnicker MJ. Percent positive rate of Lyme real-time polymerase chain reaction in blood, cerebrospinal fluid, synovial fluid, and tissue. *Diagn Microbiol Infect Dis*. 2008;62(4):464-466
8. Centers for Disease Control and Prevention (CDC). Lyme disease--United States, 1995. *MMWR Morb Mortal Wkly Rep*. 1996;45(23):481-484

Performance**Method Description**

Nucleic acid is extracted from clinical specimens using the automated MagNA Pure bead-based system (Roche Molecular System). The extract is then transferred to a 96-well LightCycler 480 dish for amplification. The LightCycler 480 is an automated instrument that amplifies and monitors the development of target nucleic acid (amplicon) after each polymerase chain reaction (PCR) cycle. The DNA target for PCR assay is the 283-base pairs plasminogen-binding protein gene (*OppA2*), which is present at a frequency of one copy per organism in all 4 confirmed disease-causing species of the *Borrelia burgdorferi* sensu lato genogroup (*B burgdorferi* sensu stricto, *Borrelia afzelii*, *Borrelia garinii* and *Borrelia mayonii*). A specific base pair DNA target sequence is amplified by PCR. The detection of amplicon is based on fluorescence resonance energy transfer, which utilizes one hybridization probe with a donor fluorophore, fluorescein, at the 3' end, and another hybridization probe with an acceptor fluorophore, LC-Red 610, at the 5' end. When the target amplicon is present, the LC-Red 610 emits a measurable and quantifiable light signal at a specific wavelength. Presence of the specific organism nucleic acid may be confirmed by performing a melting curve analysis of the amplicon. Using features of the melting curve analysis, the assay primers and specific hybridization probes are able to detect and differentiate *B burgdorferi* sensu stricto from *B mayonii*, *B afzelii*, and *B garinii*, although the melting curve analysis cannot differentiate between *B afzelii* and *B garinii*.(Unpublished Mayo method)

PDF Report

No

Day(s) Performed

Monday, Wednesday, Friday

Report Available

1 to 4 days

Specimen Retention Time

4 weeks

Performing Laboratory Location

Mayo Clinic Health System in Eau Claire

Fees & Codes**Fees**

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

87476

87798 x 2

87801 (if appropriate for government payers)

LOINC® Information

Test ID	Test Order Name	Order LOINC® Value
PBORR	Lyme Disease PCR	94253-2

Result ID	Test Result Name	Result LOINC® Value
SRC71	Specimen Source	31208-2
23635	B. burgdorferi PCR	94250-8
38288	B. mayonii PCR	94251-6
38289	B. garinii/B. afzelii PCR	94252-4
38323	Lyme CSF Comment	59464-8